Galapagos (GLPG) announced the proposed appointment of Gino Santini as a non-executive independent director, with the intention to appoint him as chair of its board of directors, subject to shareholder approval at the annual shareholders’ meeting on April 28. If elected, Gino Santini will replace current director and chair Jerome Contamine, whose mandate as a member of the board of directors ends immediately after the AGM on April 28.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLPG:
- Galapagos in partnership discussions with Gilead after Ouro deal
- Galapagos Seeks Strategic Tie-Up With Gilead Around Ouro Medicines Deal and T Cell Engager OM336
- M&A News: Gilead Bets $2B+ on Ouro Medicines to Power Immunology Growth
- Galapagos Discloses Bank of America’s Stake Drop Below 5% Threshold
- Galapagos Discloses Bank of America Crossing 5% Ownership Threshold in March 2026